Clinical Trial

Increasing Access to Fertility Preservation for Women with Breast Cancer

Study acronym: EVAPREF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The EVAPREF project aims to increase access to fertility preservation by developing an approach to improve and evaluate existing information and coordination tools developed by the Pays-de-la-Loire and Occitanie Regional Cancer networks. First, the investigators will use a qualitative, iterative, user-centered and participatory approach to improve the current tools and create training content for the physicians who will use these tools. Second, the investigators will conduct a randomized stepped wedge trial of women under 40 newly treated with chemotherapy for breast cancer. The investigators will evaluate the rate of fertility preservation consultation before and after implementation of the improved tools, over a 30-month period from mid-2023 to the end of 2025. Finally, in a third step, the investigators will study their approach (context-sensitive implementation analysis) and provide key elements for its transferability to other contexts and in particular to other Regional Cancer networks in France.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-04; most recent amendment 2024-12-06.
Trial Details
NCT Number NCT05989776
Lead Sponsor University Paul Sabatier of Toulouse
Collaborators: National Cancer Institute, France, Institut Claudius Regaud, Réseau Onco-Occitanie, Réseau ONCOPL
Conditions Breast Cancer
Enrollment 750 participants
Start Date 2022-06-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-12